-DOCSTART- -X- O
Myocardial -X- _ O
infarction -X- _ O
is -X- _ O
one -X- _ O
of -X- _ O
the -X- _ O
most -X- _ O
common -X- _ O
human -X- _ O
cerebrovascular -X- _ O
conditions -X- _ O
and -X- _ O
frequently -X- _ O
leads -X- _ O
to -X- _ O
ischemic -X- _ O
stroke. -X- _ O
Evidence -X- _ O
has -X- _ O
indicated -X- _ O
that -X- _ O
magnetic -X- _ B-Comparison
resonance -X- _ I-Comparison
imaging -X- _ I-Comparison
( -X- _ I-Comparison
MRI -X- _ I-Comparison
) -X- _ I-Comparison
is -X- _ O
a -X- _ O
potential -X- _ O
method -X- _ O
for -X- _ O
the -X- _ O
diagnosis -X- _ O
of -X- _ O
patients -X- _ O
with -X- _ O
cardiovascular -X- _ O
injury. -X- _ O
However -X- _ O
, -X- _ O
the -X- _ O
efficacy -X- _ O
of -X- _ O
MRI -X- _ B-Comparison
in -X- _ O
diagnosing -X- _ O
patients -X- _ O
with -X- _ O
myocardial -X- _ O
infarction -X- _ O
requires -X- _ O
to -X- _ O
be -X- _ O
improved. -X- _ O
In -X- _ O
the -X- _ O
present -X- _ O
study -X- _ O
, -X- _ O
a -X- _ O
novel -X- _ O
nano-size -X- _ O
contrast -X- _ O
agent -X- _ O
, -X- _ O
a -X- _ O
chitosan -X- _ O
/ -X- _ O
Fe -X- _ O
( -X- _ O
3 -X- _ O
) -X- _ O
O -X- _ O
( -X- _ O
4 -X- _ O
) -X- _ O
-enclosed -X- _ O
albumin -X- _ O
( -X- _ O
CFEA -X- _ O
) -X- _ O
, -X- _ O
was -X- _ O
introduced -X- _ O
that -X- _ O
was -X- _ O
used -X- _ O
to -X- _ O
quantify -X- _ O
blood -X- _ O
volume -X- _ O
and -X- _ O
permeability -X- _ O
in -X- _ O
the -X- _ O
infarcted -X- _ O
myocardium. -X- _ O
A -X- _ O
total -X- _ O
of -X- _ O
68 -X- _ O
patients -X- _ O
with -X- _ O
suspected -X- _ B-Patient
myocardial -X- _ I-Patient
infarction -X- _ I-Patient
were -X- _ O
recruited -X- _ O
to -X- _ O
analyze -X- _ O
the -X- _ O
efficacy -X- _ O
of -X- _ O
MRI -X- _ B-Intervention
combined -X- _ I-Intervention
with -X- _ I-Intervention
CFEA -X- _ I-Intervention
( -X- _ I-Intervention
MRI-CFEA -X- _ I-Intervention
) -X- _ I-Intervention
. -X- _ O
All -X- _ O
patients -X- _ O
received -X- _ O
diagnosis -X- _ O
by -X- _ O
MRI -X- _ B-Comparison
and -X- _ O
MRI-CFEA. -X- _ B-Intervention
It -X- _ O
was -X- _ O
revealed -X- _ O
that -X- _ O
MRI-CFEA -X- _ B-Intervention
provided -X- _ O
a -X- _ O
higher -X- _ O
signal -X- _ O
intensity -X- _ O
than -X- _ O
MRI -X- _ B-Comparison
in -X- _ O
the -X- _ O
same -X- _ O
patients. -X- _ O
It -X- _ O
was -X- _ O
demonstrated -X- _ O
that -X- _ O
the -X- _ O
diagnostic -X- _ B-Outcome
efficacy -X- _ I-Outcome
of -X- _ I-Outcome
MRI-CFEA -X- _ I-Outcome
for -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
myocardial -X- _ I-Outcome
infarction -X- _ I-Outcome
was -X- _ I-Outcome
higher -X- _ I-Outcome
than -X- _ I-Outcome
that -X- _ I-Outcome
of -X- _ I-Outcome
MRI -X- _ I-Outcome
( -X- _ I-Outcome
P -X- _ I-Outcome
< -X- _ I-Outcome
0.05 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ O
By -X- _ O
MRI-CFEA -X- _ B-Intervention
, -X- _ O
50 -X- _ O
/ -X- _ O
68 -X- _ O
of -X- _ O
cases -X- _ O
with -X- _ O
myocardial -X- _ O
infarction -X- _ O
were -X- _ O
diagnosed -X- _ O
, -X- _ O
providing -X- _ O
a -X- _ O
significantly -X- _ O
higher -X- _ O
diagnostic -X- _ O
rate -X- _ O
compared -X- _ O
with -X- _ O
the -X- _ O
38 -X- _ O
/ -X- _ O
68 -X- _ O
of -X- _ O
cases -X- _ O
diagnosed -X- _ O
by -X- _ O
contrast-enhanced -X- _ O
MRI -X- _ B-Comparison
( -X- _ O
P -X- _ O
< -X- _ O
0.01 -X- _ O
) -X- _ O
. -X- _ O
MRI-CFEA -X- _ B-Outcome
successfully -X- _ I-Outcome
discriminated -X- _ I-Outcome
the -X- _ I-Outcome
infarcted -X- _ I-Outcome
regions -X- _ I-Outcome
based -X- _ I-Outcome
on -X- _ I-Outcome
a -X- _ I-Outcome
decreased -X- _ I-Outcome
fractional -X- _ I-Outcome
blood -X- _ I-Outcome
volume -X- _ I-Outcome
and -X- _ I-Outcome
increased -X- _ I-Outcome
permeability-surface -X- _ I-Outcome
( -X- _ I-Outcome
PS -X- _ I-Outcome
) -X- _ I-Outcome
area -X- _ I-Outcome
product -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
infarcted -X- _ I-Outcome
myocardium. -X- _ I-Outcome
A -X- _ B-Outcome
pharmacodynamics -X- _ I-Outcome
analysis -X- _ I-Outcome
indicated -X- _ I-Outcome
that -X- _ I-Outcome
CFEA -X- _ I-Outcome
was -X- _ I-Outcome
eliminated -X- _ I-Outcome
within -X- _ I-Outcome
24 -X- _ I-Outcome
h -X- _ I-Outcome
in -X- _ I-Outcome
all -X- _ I-Outcome
individuals. -X- _ I-Outcome
In -X- _ O
conclusion -X- _ O
, -X- _ O
the -X- _ O
present -X- _ O
study -X- _ O
provided -X- _ O
a -X- _ O
novel -X- _ O
method -X- _ O
to -X- _ O
diagnose -X- _ O
infarcted -X- _ O
myocardium -X- _ O
for -X- _ O
patients -X- _ O
with -X- _ O
myocardial -X- _ O
infarction -X- _ O
, -X- _ O
providing -X- _ O
an -X- _ O
imaging -X- _ O
biomarker -X- _ O
for -X- _ O
the -X- _ O
assessment -X- _ O
of -X- _ O
endothelial -X- _ O
dysfunction -X- _ O
in -X- _ O
the -X- _ O
clinic -X- _ O
. -X- _ O

